NorwayNorway

Clavis Pharma ASA gets cash injection

22.12.2009

Oslo – Norwegian drug delivery specialist Clavis Pharma ASA has received an unsecured loan of NOK20m ($3.2m) from Innovation Norway to kick-off a phase III registration trial with elacytarabine in patients with late-stage acute myeloid leukaemia (AML). The lipid-conjugated form of the anti-cancer drug cytarabine (Ara-C) prolonged median survival by 5.3 months compared to 1.5 months with standard treatment in a phase II study with 594 volunteers. Remission rates significantly increased (14.8% vs. 2.5%), and short-term mortality was substantially lowered (13% vs. 25%). The registration trial will start in the first half of 2010. Clavis Pharma announced that it has also received approval to enrol patients in a phase II study for elacytarabine in combination with idarubicin in AML patients who have failed their first course of treatment. At the end of November, Clavis licensed out its pancreatic cancer drug CP-4126 for $380m to US-based Clovis Oncology (more…).

NorwayNorway

12.05.2010

Oslo – In Norway, a discussion has begun on how to continue to support biotechnology after the current National Programme for Research in Functional Genomics in Norway (FUGE) comes to a close in 2011. Efforts to draw up a...

NorwayNorway

23.04.2010

Oslo – Norwegian cancer specialist Clavis Pharma ASA announced yesterday that its US-based development partner Clovis Oncology for CP-4126 has signed an agreement with Ventana Medical Systems, Inc. to develop a companion...

NorwayNorway

06.03.2010

Oslo/Levanger – A report released by the Research Council of Norway (RCN) proposes setting up a national biobank company in Norway. After analysing ethical, judicial and political arguments, the study ordered by the Norwegian...

NorwayNorway

01.02.2010

Cancer drug developer Clavis Pharma ASA (Oslo) has appointed Olav Hellebø as its new CEO. Hellebø, who joined Clavis Pharma from UCB at the beginning of February, is an experienced pharmaceutical executive who has held senior...

NorwayNorway

04.01.2010

Oslo – Norwegian drug delivery specialist Clavis Pharma ASA has received an unsecured loan of NOK20m (EUR2.4m) from the governmental body Innovation Norway to kick-off a Phase III registration trial with elacytarabine in 350...

NorwayNorway

25.11.2009

Oslo/Boulder – Norwegian drugmaker Clavis Pharma has inked a cancer drug development deal worth around US$380m with US-based Clovis Oncology, a newly formed oncology company led by former Pharmion Corporation executives. The deal...

NorwayNorway

19.09.2009

Oslo – Norway’s Algeta ASA surprised analysts with a EUR560m licensing pact for the company’s lead drug – an experimental radiotherapy that targets cancerous bone cells. Licensing partner Bayer Schering Pharma will pay US$61m in...

NorwayNorway

13.07.2009

Oslo – Prof. Harald Stenmark, head of the Centre for Cancer Biomedicine at the Norwegian Radium Hospital, has received one of the Advanced Grants distributed by the European Research Council. The oncologist will now receive...

NorwayNorway

13.07.2009

Oslo – Clavis Pharma ASA, a Norwegian drug developer focused on cancer therapies, has reported that it has received EUR14m (NOK 129m) in additional funding through a private placement of 10.7 million shares led by Carnegie ASA...

Displaying results 21 to 30 out of 92

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/2/article/clavis-pharma-asa-gets-cash-injection.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products